Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Saizo Fujmoto"'
Autor:
Saizo Fujmoto, Kazutoshi Fujita, Mitsuhisa Nishimoto, Mamoru Hamaguchi, Ken Kuwahara, Mamoru Hashimoto, Shogo Adomi, Takafumi Minami, Masahiro Nozawa, Kazuhiro Yoshimura, Hirotsugu Uemura
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3176-3179 (2023)
Abstract Enzalutamide, apalutamide, and darolutamide are currently recommended for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC), but cross‐resistance of androgen receptor‐axis‐targeted therapies (ARAT) occurs.
Externí odkaz:
https://doaj.org/article/f9ff1f67dce24f7fabefde0baaee780d
Autor:
Saizo Fujmoto, Kazutoshi Fujita, Mitsuhisa Nishimoto, Mamoru Hamaguchi, Ken Kuwahara, Mamoru Hashimoto, Shogo Adomi, Takafumi Minami, Masahiro Nozawa, Kazuhiro Yoshimura, Hirotsugu Uemura
Publikováno v:
Cancer medicineREFERENCES.
Enzalutamide, apalutamide, and darolutamide are currently recommended for patients with non-metastatic castration-resistant prostate cancer (nmCRPC), but cross-resistance of androgen receptor-axis-targeted therapies (ARAT) occurs. Because darolutamid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30863a9acf44ee4fa9fd1671236c4fbd
https://pubmed.ncbi.nlm.nih.gov/36043427
https://pubmed.ncbi.nlm.nih.gov/36043427